Christina Hartl has a diverse work experience, beginning in 2009 as an intern at Entelechon GmbH. Christina then interned at Amgen Research Munich GmbH in 2011, followed by dkfz - German Cancer Research Center in 2012, Cold Spring Harbor Laboratory in 2013, and the Max Planck Institute for Medical Research in 2013. In 2014, they interned in Cancer Immunotherapy at the Translational Research Institute Australia. From 2015 to 2019, they held the roles of Postdoctoral Scientist and Graduate Student at the Dana-Farber Cancer Institute, and then Senior Scientist and Scientist at iOmx Therapeutics AG.
Christina Hartl's education history includes a Bachelor of Science in Molecular Biotechnology from Heidelberg University (2009-2012), a Master of Science in Molecular Biotechnology from Heidelberg University (2012-2015), a Doctor of Philosophy in Biochemistry from University of Tübingen (2015-2019), and a Postdoctoral Fellowship in Cancer Biology from Harvard Medical School (2019).
April, 2022 - present
October, 2019